Eli Lilly And Co (N:LLY)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: Lilly Corporate Ctr
Drop Code 1094, Lilly Corporate Ctr
INDIANAPOLIS IN 46285-0001
Tel: N/A
Website: https://www.lilly.com
IR: See website
<
Key People
David A. Ricks
Chairman of the Board, President, Chief Executive Officer
Jacob S. Van Naarden
Executive Vice President, Chief Executive Officer - Loxo Oncology at Lilly, President - Lilly Oncology
Anat Ashkenazi
Chief Financial Officer, Executive Vice President
Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Alonzo Weems
Executive Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer
Anat Hakim
Executive Vice President, General Counsel, Secretary
Eric Dozier
Executive Vice President - Human Resources and Diversity
Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Patrik Jonsson
Executive Vice President, President of Lilly Diabetes and Obesity and President of Lilly USA
Johna L. Norton
Executive Vice President - Global Quality
   
Business Overview
Eli Lilly and Company is engaged in drug manufacturing businesses. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. The Company manufactures and distributes its products through facilities in the United States (U.S.), including Puerto Rico, and in Europe and Asia. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer.
Financial Overview
For the fiscal year ended 31 December 2023, Eli Lilly And Co revenues increased 20% to $34.12B. Net income decreased 16% to $5.24B. Revenues reflect Diabetes-Mounjaro segment increase from $482.5M to $5.16B, Oncology-Verzenio segment increase of 56% to $3.86B, U.S. segment increase of 20% to $21.79B, Europe segment increase of 44% to $6.17B. Net income was offset by Acquired in-Process Research and Deve increase from $908.5M to $3.8B (expense).
Employees: 43,000 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $761,956M as of Dec 31, 2023
Annual revenue (TTM): $34,124M as of Dec 31, 2023
EBITDA (TTM): $11,853M as of Dec 31, 2023
Net annual income (TTM): $5,240M as of Dec 31, 2023
Free cash flow (TTM): -$7,221M as of Dec 31, 2023
Net Debt Last Fiscal Year: $22,298M as of Dec 31, 2023
Shares outstanding: 950,766,100 as of Feb 28, 2024
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.